Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Umbilical cord-derived mesenchymal stromal cells for COVID-19-related ARDS
jRCT1080225369Phase 1Completed
- Sponsor
- Human Life CORD
- Start
- Aug 2020
- Countries
- 1
01
Overview
Phase 1, open-label trial of umbilical cord-derived mesenchymal stromal cells in coronavirus disease 2019 (COVID-19) and acute respiratory distress syndrome (ARDS) (2 arms), sponsored by Human Life CORD. Started Aug 2020; status: completed.
02
Drugs
umbilical cord-derived mesenchymal stromal cells
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on jRCT1080225369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080225369.